Ipsen said Monday that it has reached an agreement to acquire U.S. oncology drugmaker Epizyme Inc. for a cash consideration of around $247 million.
The French biopharmaceutical company IPN,
The primary focus of the acquisition is the lead medicine, Tazverik (tazemetostat), a chemotherapy-free EZH2(a) inhibitor, which was granted accelerated approval by the Food and Drug Administration in 2020, Ipsen said.
The acquisition is expected to be moderately dilutive to Ipsen’s operating earnings until the end of 2024 given research-and-development costs, Ipsen said.
The transaction is expected to close by the end of the third quarter this year, dependent on regulatory approval, the company said.
Write to Joshua Kirby at [email protected]; @joshualeokirby
